In 2005, 19-year-old Nick Currey of Ridgewood, New Jersey, lost his life to Ewing sarcoma, a cancer of the bone (and at times soft tissue) that develops in young people. Nick’s parents, Nancy and Ralph Currey, established the Nick Currey Fund in his memory to support research that will speed the day when no young person’s life is cut short by Ewing sarcoma.
Nick survived leukemia as a child (he was treated between the ages of four and six) only to succumb to Ewing sarcoma as a young adult. Being a leukemia survivor may well have caused Nick to develop Ewing sarcoma. Childhood cancer survivors are nine times more likely than the general population to develop a sarcoma. In addition, the lifetime dosages of chemotherapy Nick received directly contributed to his death. His body could not survive the intense chemotherapy associated with the autologous stem cell transplant that was his last, best hope. If more targeted, less toxic therapies had been available, Nick might be alive today.
While survival rates for childhood cancer have shown impressive improvement, those statistics only capture patients who survive five or 10 years. They do not reflect the survivors like Nick who suffer an early death from secondary cancers or devastating long-term side effects such as heart disease that result from the toxicity of current therapies. The Nick Currey Fund is dedicated to finding new and improved therapies for Ewing sarcoma that either represent a real cure or are less toxic than conventional chemotherapy.
Donations to the Nick Currey Fund will be used exclusively to fund Ewing sarcoma research projects selected by the Currey family in consultation with Michael Harris, MD, head of Pediatric Hematology and Oncology at Hackensack University Medical Center and other leading pediatric oncologists. Dr. Harris was Nick’s oncologist and close friend for 15 years. To donate to the Nick Currey Fund, click here.
To date, The Nick Currey Fund has raised over $1 million and has funded or is funding a number research projects aimed at improving outcomes for children, adolescents and young adults diagnosed with Ewing sarcoma. For further information, see “Supporting Ewing Sarcoma Research.”
For more information please contact email@example.com.